Skip to content

Excimer Laser Trabeculostomy Glaucoma Treatment Study

A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Effectiveness of the ELIOS System to Reduce Intraocular Pressure in Patients With Primary Open-Angle Glaucoma Undergoing Cataract Surgery

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04899063
Acronym
ELTGTS
Enrollment
318
Registered
2021-05-24
Start date
2021-05-10
Completion date
2025-07-29
Last updated
2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Primary Open Angle

Brief summary

Evaluation of the safety and effectiveness of the ELIOS System procedure to reduce intraocular pressure (IOP) in adult subjects with mild to moderate primary open-angle glaucoma (POAG) undergoing cataract surgery

Interventions

Treatment with the ELIOS System

Sponsors

Elios Vision, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of mild to moderate POAG * Operable cataract, eligible for phacoemulsification with a BCVA of 20/40 or worse * Medicated IOP of \<=24 mmHg * Unmedicated diurnal IOP of \>=22 mmHg and \<=34 mmHg * Shaffer angle grade of III or IV * CD ratio \<=0.8 * At least 45 years old

Exclusion criteria

* Closed-angle and secondary glaucomas * Prior incisional glaucoma surgery, intraocular surgery, or corneal surgery * Cannot undergo medication washout in the study eye * Diagnosis of degenerative visual disorders * Non-study eye with BCVA worse than 20/80 * Known corticosteroid responder * Pregnant or nursing women; or women of childbearing potential not using medically acceptable birth control

Design outcomes

Primary

MeasureTime frameDescription
Proportion of subjects who achieve a decrease in medication-free mean diurnal IOP (DIOP) from baseline of at least 20%24 MonthProportion of subjects who achieve a decrease in medication-free mean diurnal IOP (DIOP) from baseline of at least 20%

Secondary

MeasureTime frameDescription
Mean Change in medication-free DIOP from baseline24 MonthMean change in medication-free DIOP from baseline

Countries

United States

Contacts

STUDY_DIRECTORIqbal (Ike) Ahmed, MD

Prism Eye Institute

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 10, 2026